Vestmark Advisory Solutions Inc. decreased its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 4.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 23,373 shares of the company’s stock after selling 1,000 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Ionis Pharmaceuticals were worth $1,400,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IONS. DNB Asset Management AS acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth about $872,000. WINTON GROUP Ltd acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at about $465,000. Campbell & CO Investment Adviser LLC acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at about $365,000. PFS Investments Inc. raised its position in Ionis Pharmaceuticals by 208.5% in the 2nd quarter. PFS Investments Inc. now owns 15,644 shares of the company’s stock valued at $1,010,000 after purchasing an additional 10,573 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Ionis Pharmaceuticals by 282.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 29,364 shares of the company’s stock valued at $1,887,000 after purchasing an additional 21,688 shares in the last quarter. 88.41% of the stock is currently owned by hedge funds and other institutional investors.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 22,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the completion of the sale, the chairman now directly owns 79,634 shares of the company’s stock, valued at approximately $5,695,423.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.40% of the company’s stock.

Shares of IONS traded up $0.33 during mid-day trading on Tuesday, reaching $56.98. The company’s stock had a trading volume of 641,300 shares, compared to its average volume of 1,145,895. Ionis Pharmaceuticals Inc has a 12-month low of $48.27 and a 12-month high of $86.58. The stock has a market cap of $8.03 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 2.45 and a beta of 1.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31. The company’s 50 day moving average is $57.77 and its 200 day moving average is $64.17.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.49. The firm had revenue of $168.00 million for the quarter, compared to the consensus estimate of $152.47 million. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. As a group, sell-side analysts anticipate that Ionis Pharmaceuticals Inc will post 1.67 EPS for the current fiscal year.

A number of equities research analysts have issued reports on IONS shares. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $87.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, November 7th. BMO Capital Markets reduced their price target on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 24th. Morgan Stanley downgraded Ionis Pharmaceuticals from an “equal” rating to a “weight” rating and dropped their price objective for the company from $63.00 to $48.00 in a report on Thursday, November 7th. Finally, Piper Jaffray Companies dropped their price objective on Ionis Pharmaceuticals from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $73.45.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Recommended Story: Technical Analysis

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.